FDA-cleared profile

Contour ProtegeAI

MIM Software Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.

Clinical role
Radiotherapy contouring, treatment planning, treatment management, image processing, or session support under qualified review and approval.
Images and patients
Radiotherapy Planning Imaging · Normal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR
Key limitation
Keep in mind: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Normal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR Input: Supported CT or MR images, structures, prescriptions, treatment plans, registrations, and treatment-session data.
  • Who uses it?Intended users: Radiation oncologists, medical physicists, dosimetrists, therapists, and other qualified radiation professionals.
  • What does the software produce?Output: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
  • What is its most important limitation?Key limitation: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.

Clinical takeaway. Clinical role: Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports segmentation testing on 286 CT images and 72 MR images from institutions disjoint from the training data, with Contour ProtégéAI and the MIM predicate device both segmenting the test sets. A non-inferiority test of mean Dice coefficient against the predicate showed non-inferiority for all neural network models at a limit of 0.1 Dice. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Radiotherapy contouring, treatment planning, treatment management, image processing, or session support under qualified review and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT or MR images, structures, prescriptions, treatment plans, registrations, and treatment-session data.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology settings within the labeled workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiation oncologists, medical physicists, dosimetrists, therapists, and other qualified radiation professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports segmentation testing on 286 CT images and 72 MR images from institutions disjoint from the training data, with Contour ProtégéAI and the MIM predicate device both segmenting the test sets. A non-inferiority test of mean Dice coefficient against the predicate showed non-inferiority for all neural network models at a limit of 0.1 Dice. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "For testing, 286 images were used to evaluate the neural network models that segmented CT images, while 72 images were used to evaluate for the MR segmentation network." … "In all cases, the test images were gathered from a different and disjoint set of institutions from the training data.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports segmentation testing on 286 CT images and 72 MR images from institutions disjoint from the training data, with Contour ProtégéAI and the MIM predicate device both segmenting the test sets. A non-inferiority test of mean Dice coefficient against the predicate showed non-inferiority for all neural network models at a limit of 0.1 Dice. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "For testing, 286 images were used to evaluate the neural network models that segmented CT images, while 72 images were used to evaluate for the MR segmentation network." … "In all cases, the test images were gathered from a different and disjoint set of institutions from the training data.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K193252 FDA decision evidence package for Contour ProtegeAI

  • DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
  • PopulationNormal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR
  • Scopeexact submission
  • Tested versionContour ProtegeAI configuration described in K193252
  • IndependenceSponsor or vendor study

K193252

FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K193252 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT or MR images, structures, prescriptions, treatment plans, registrations, and treatment-session data.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K193252: Contour ProtegeAI

  2. Routing

    Source context, not route validation: The exact FDA package describes Contour ProtégéAI processing CT and MR images as supported by ACR/NEMA DICOM 3.0, using the MIMcloud service for data management and transfer, and creating contours for applications including transfer to radiation therapy treatment planning systems and archiving. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Contour ProtégéAI is used by trained medical professionals as a tool to aid in the automated processing of digital medical images of modalities CT and MR, as supported by ACR/NEMA DICOM 3.0." … "The creation of contours using machine-learning algorithms for applications including, but not limited to, quantitative analysis, aiding adaptive therapy, transferring contours to radiation therapy treatment planning systems, and archiving contours for patient follow-up". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K193252: Contour ProtegeAI

  3. AI processing

    Source context, not route validation: The exact FDA package describes Contour ProtégéAI as deployed on a remote server using the MIMcloud service for data management and transfer, and as operating on Windows, Mac, and Linux computer systems. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "It is designed for use in the processing of medical images and operates on Windows, Mac, and Linux computer systems." … "Contour ProtégéAI is deployed on a remote server using the MIMcloud service for data management and transfer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K193252: Contour ProtegeAI

  4. Returned objects

    Source context, not route validation: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K193252: Contour ProtegeAI

  5. Viewer/worklist/report

    Unresolved route: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K193252: Contour ProtegeAI

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Contour ProtégéAI as deployed on a remote server using the MIMcloud service for data management and transfer, and as operating on Windows, Mac, and Linux computer systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It is designed for use in the processing of medical images and operates on Windows, Mac, and Linux computer systems." … "Contour ProtégéAI is deployed on a remote server using the MIMcloud service for data management and transfer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes Contour ProtégéAI processing CT and MR images as supported by ACR/NEMA DICOM 3.0, using the MIMcloud service for data management and transfer, and creating contours for applications including transfer to radiation therapy treatment planning systems and archiving. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Contour ProtégéAI is used by trained medical professionals as a tool to aid in the automated processing of digital medical images of modalities CT and MR, as supported by ACR/NEMA DICOM 3.0." … "The creation of contours using machine-learning algorithms for applications including, but not limited to, quantitative analysis, aiding adaptive therapy, transferring contours to radiation therapy treatment planning systems, and archiving contours for patient follow-up". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
MIM Software's security page states SOC 2 Type 2 status, penetration testing and continuous vulnerability scanning of released products, coordinated vulnerability disclosure and a public security advisories page. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
Only radiation oncologists, medical physicists, dosimetrists, therapists, and other qualified radiation professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K193252 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K193252 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

exact submission · checked 2026-09-04

No exact-product price or reimbursement determination was promoted.

Lifecycle monitoring

Monitor K193252 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K193252
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Normal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-07-02
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor documentation, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K193252: Contour ProtegeAI

    U.S. Food and Drug Administration - Published 2020-07-02 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. MIM Software Security

    MIM Software - Accessed 2026-10-25

    Scope: security

Research history

  1. K193252 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250035

Contour ProtégéAI+

MIM Software Inc.

Authorized purpose: Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive; users must review and edit contours, and the device is not intended to detect or contour lesions.

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomical regions; prostate, seminal vesicles, and urethra on T2 MR
Decision
2025-02-03
FDA-cleared K231765

Contour ProtégéAI

MIM Software Inc.

Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Decision
2023-11-08
FDA-cleared K223774

Contour ProtégéAI

MIM Software Inc.

Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, machine-learning contour creation for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segmentation across CT locations, and segmentation of the prostate, seminal vesicles, and urethra on T2-weighted MR images.

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Decision
2023-04-06
FDA-cleared K213976

Contour ProtégéAI

MIM Software Inc.

Authorized purpose: Contour ProtégéAI creates machine-learning contours from CT and MR DICOM images to support quantitative analysis, adaptive therapy, radiotherapy planning, archiving, and follow-up; professionals must visualize, review, and edit contours, and the software is not intended to detect or contour lesions.

Modality
Radiotherapy Planning Imaging
Anatomy
Normal structures in labeled CT locations; prostate, seminal vesicles, and urethra on T2 MR
Decision
2022-02-03

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history